Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. MEPSEVII
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

MEPSEVII

Medicine - Posted on Jul 01 2020 - Updated on Jul 01 2020
Active substance (DCI)
  • vestronidase alfa
history (2)
  • 6/24/20

    MEPSEVII

    Reevaluation. Unfavourable opinion for reimbursement in the treatment of non-neurological manifestations of Mucopolysacchari...
    CAV :
    54321
    icône flèche
  • 2/27/19

    MEPSEVII (vestronidase alfa)

    Intérêt clinique insuffisant pour justifier son remboursement dans la mucopolysaccharidose de type VII ou maladie de Sly. ME...
    icône flèche
Technical information
ATC code
  • A16AB18
Manufacturer
ULTRAGENYX FRANCE SAS
Presentation

MEPSEVII 2 mg/ml, solution à diluer pour perfusion (code CIS : 61759695)
1 flacon(s) en verre de 5 ml (CIP : 34009 550 578 6 4)

All our publications
    Congenital, genetic and rare diseases Drug therapy Metabolic diseases Paediatrics

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
PArS6xVC3ZRGWLu3